bluuebunny/crossref_metadata_2025_split huggingface dataset:
Chromosomal abnormalities in adult non‐endemic burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature
Authors: Kornblau Steven M. , Goodacre Angela , Cabanillas Fernando 
Published: February 2007

AbstractTumour cell karyotypes from patients with Burkitt lymphoma (BL) or Burkitt's type leukemia (ALL3) were studied for correlation with survival, bone marrow and cerebral spinal fluid involvement (CSF), human immunodeficiency virus (HIV) serology, and for recurrent cytogenetic abnormalities.The records of 22 patients with BL from our institution and of 148 cases of BL and ALL3 reported in the literature with karyotypes were evaluated for clinical and cytological features.Overall survival was only 28 per cent and 88 per cent of deaths occurred within the first nine months after diagnosis. Those who survived at least 18 months were unlikely to relapse. Age and gender did not significantly affect survival. Patients presenting with advanced Ann Arbor stage, bone marrow or CSF involvement had lower survival rates. The association of translocations involving chromosome band 8q24 with this disease is confirmed. Sixty‐two per cent of karyotypes had t(8;14)(q24;q32) translocations; the recognized variant translocations t(8;22)(q24;q11) and t(2;8)(p12;q24) affected 12 per cent and 9 per cent respectively. Seventeen percent had abnormal karyotypes but no classic translocation. Patients with variant translocations had the poorest survival rates, and those with the classic t(8;14)(q24;q32) did the best. Despite a small sample size, the variant translocation t(8;22)(q24;q11) appeared to occur at an increased frequency in the patients with AIDS. In the entire group, recurrent involvement of chromosome regions 1q2, 6q11–14 and 17pl suggests that alteration of genes at these loci, B Cell Growth Factor (BCGF) at 1q2 and p53 on 17p, may contribute to the development and progression of this tumour. Similarly, the frequent trisomies of chromosomes 7, 8, 12 and 18 may indicate an effect on tumour cell growth due to increased gene dosage. Trisomy 12 was found in eight tumours, five from patients with AIDS, suggesting that chromosome 12 has a site or gene whose allelic dosage is selected for in AIDS related lymphoma cells.Cytogenetic studies of adult Burkitt lymphoma and leukemia suggest several likely loci for gene alterations that in conjunction with myc translocations can lead to tumorigenesis.
Etoposide, 6‐thioguanine and idarubicin, an oral combination regimen (ETI) for the induction treatment of acute leukemia
Authors: Ruutu Tapani , Elonen Erkki 
Published: February 2007

AbstractTwenty patients with advanced acute leukemia (16 acute myeloid leukemia (AML), three myeloid blast crisis (BC) of chronic myeloid leukemia (CML), one acute lymphatic leukemia) were treated with a peroral regimen consisting of etoposide 80 mg/m2 and 6‐thioguanine 100 mg/m2 twice daily for 5 days, and idarubicin 15 mg/m2 once daily for 3 days (ETI). Two AML patients were in first relapse. All the other patients with acute leukemia had a later relapse or were refractory to primary or salvage treatment. One to six ETI cycles were given. Four AML patients achieved remission and one patient with BC of CML entered the second chronic phase. Clearing of the blood of leukemic cells was seen in seven additional patients. Infection was the most common complication, gastrointestinal toxicity was not a major problem. In conclusion, peroral ETI treatment has a marked antileukemic effect even in an advanced disease, and the toxicity is moderate and well acceptable.
An alternating chemotherapy combination (macoble) for intermediate and high‐grade non‐hodgkin's lymphoma
Authors: Harding M. , McNulty L. , Paul J. , Lee F. , Dunlop D. , Soukop M. 
Published: February 2007

AbstractFrom June 1983 to February 1986, 48 patients with intermediate or high‐grade non‐Hodgkin's lymphomas (NHL) received a CHOP based combination with the addition of etoposide on days 1 and 2, bleomycin days 1 and 10 and methotrexate 1.5 g/m2 on day 10 (MACOBLE). Their median age was 59 years, 20 (42 per cent) had an ECOG performance status (PS) of 2 or 3, 24 (50 per cent) had stage IV disease, 25 (52 per cent) B symptoms and 21 (44 per cent) bulk (> 10 cm) disease.With a median follow‐up of 62 months, 12 patients are alive, 10 of whom are disease‐free. Median overall survival was 13 months (95 per cent confidence interval 6–23 months) with actuarial 5‐year survival of 25 per cent (95 per cent confidence interval 13–37 per cent). Factors associated with inferior survival were ECOG PS 2 or 3 (P = 0.004), B symptoms (P = 0.013) and bulk disease (P = 0.017).These data suggest that, when treating an unselected patient population, attempts to increase the intensity of first‐line chemotherapy may not improve the outcome.
Increase of serum interleukin‐2 and regression of myeloma after rhGM‐CSF treatment of drug induced bone marrow aplasia
Authors: Bernell Per , Pisa Pavel , Hast Robert , Hansson Mona , Sandstedt Bengt , Stenke Leif 
Published: February 2007

AbstractRecombinant human granulocyte/macrophage colony‐stimulating factor (rhGM‐CSF) was administered to a patient with multiple myeloma (IgA, stage IIA) who had a chemotherapy‐induced bone marrow aplasia with granulocytopenia complicated by severe pneumonia and septicemia. The rhGM‐CSF was given as i.v. infusions, 300–400 μg daily, for three weeks. The patient responded both hematologically and clinically with improved granulocyte counts and clearance of massive pulmonary infiltrates. We also observed a partial remission of the myeloma with decreasing s‐IgA levels and reduced plasma cell infiltration of the bone marrow during a period of up to four months after the rhGM‐CSF treatment. Immunological studies performed during and after cytokine administration showed an increase in serum interleukin‐2 (IL‐2) levels and HLA‐DR positive T‐lymphocytes indicating an activation of the immune system. It is suggested that rhGM‐CSF induced immunological changes which may have contributed to the partial regression of the myeloma.
Second malignant neoplasms in patients with non hodgkin's lymphoma
Authors: Lishner Michael , Slingerland Joyce , Barr Joseph , Panzarella Tony , Degendorfer Pam , Sutcliffe Simon 
Published: February 2007

AbstractA retrospective review of the records of 3886 patients with non‐Hodgkin's lymphoma registered at the Princess Margaret Hospital between 1970 and 1985 was undertaken to determine the incidence of second malignant tumours. Three thousand and twenty‐one patients with a minimum documented follow‐up of 6 months from referral were identified for analysis. The overall observed/expected ratio for all cancers in patients with malignant lymphoma was 1, suggesting no increased risk of developing a second malignant neoplasm compared to the general population. When the data were analyzed independently for each tumour site, statistically significant increased risk of developing acute non lymphocytic leukemia (ANLL) (p < 0·001) and carcinoma of the tongue (p < 0·05) were found. An increased risk of lung cancer following lymphoma was detected but was not statistically significant. Survival following diagnosis of ANLL and lung cancer was similar and significantly shorter than that following the diagnosis of other second malignancies. The risk of developing a second primary cancer was significantly related to increasing patient age.
Multicentre combined chemotherapy protocol for large cell advanced non hodgkin's lymphoma
Authors: Dumont J. , Charpy‐Validire P. , Mosseri V. , Gabarre J. , Belanger C. , Turpin F. , Binet J. L. , Dreyfus F. , Fourquet A. , Janvier M. , LeDoussal M. , Missenard V. , Natali J. C. , Raphael M. , Teillet F. , Teillet‐Thiebaud F. , Tulliez M. , Varet B. , Vilcoq J. R. , Asselain B. 
Published: February 2007

AbstractBetween October 1985 and October 1989, 75 previously untreated patients with stage III and IV non Hodgkin's lymphoma, large cell type, were treated with an alternating weekly chemotherapy regimen including the following drugs: week 1: Doxorubicin, vincristine, cyclophosphamide, bleomycin, and intrathecal (i.th.) methotrexate and cytarabine; week 2: Methotrexate with leucovorin rescue; week 3: Doxorubicin, ifosfamide with mesna, etoposide, and i.th. methotrexate and cytarabine; week 4: Methotrexate with leucovorin rescue. Complete responders after three cycles according to this schedule (12 weeks) were given 18 gys cranial irradiation and randomized between one additional cycle or three monthly CHOP (consolidation treatment). Among 66 evaluable patients, 53 achieved a complete remission (CR 80 per cent) and seven a partial remission (11 per cent). There were six failures, and nine early deaths during the initial phase, mostly due to septic problems. Forty‐one of the 53 CR patients (77±3 per cent) have remained free of disease with a median follow‐up of 15 months (1–49). Eight of the 12 relapses occurred during the first year, the four others at 13, 14, 16 and 38 months respectively. The 2‐year survival was 63 per cent for the whole group, and 77 per cent for the CR group. No difference has been observed up until now between the two groups with different consolidation treatment. Therefore, this protocol seems to be able to produce a high rate of complete and durable remission. The analysis of prognostic factors suggests that some high‐risk patients should be considered for intensification therapy with the support of autologous bone marrow transplantation.
Twin‐track studies of ifosfamide and mitoxantrone (I‐M) in recurrent high grade non‐hodgkin's lymphoma and hodgkin's disease
Authors: Child J. A. , Simmons A. V. , Barnard D. L. , Parapia L. , Morgan M. , Grace R. J. , Fletcher J. , Parker D. , Norfolk D. R. , Stone J. , Stuart N. S. A. , Tucker J. , Dovey G. J. 
Published: February 2007

AbstractFifty‐seven patients, initially diagnosed as having advanced high grade non‐Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) refractory to first‐line treatment or in relapse, were treated with ifosfamide 6 g/m2, infused over 48 h, followed by mitoxantrone 12 mg/m2. The regimen repeated at three‐weekly intervals. Of 33 patients with NHL evaluable for response, 10 (30 per cent) achieved complete remission and six partial remission, giving an overall response rate of 48 per cent. Two patients subsequently went on to bone marrow transplant (BMT)—one allogeneic and the other autologous. Of 18 patients with HD evaluable for response, seven (39 per cent) achieved complete remission and six partial remission, giving an overall response rate of 72 per cent. Two of this group also went on to BMT (both autografts). The principal toxicity was neutropenia, though central nervous system changes were observed in 10 patients. The possibility of increasing the safety of the regimen by increasing the time of infusion to 72 h is discussed. Given the need to offer alternative treatment to patients in these categories, this combination (I‐M) is of value in relapsed patients, especially where options are limited because of previous multi‐drug treatment. Remissions may not be prolonged but allow the effective application of additional intensive treatment including bone marrow transplantation.
Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non‐hodgkin's lymphoma after failure of the LNH 84 regimen
Authors: Herbrecht R. , Ortiz S. , Damonte J. C. , Liu K. L. , Maloisel F. , Dufour P. , Bergerat J. P. , Oberling F. 
Published: February 2007

AbstractWe assessed the efficacy of an etoposide, ifosfamide and methotrexate combination therapy (VIM) in 24 patients failing the LNH 84 protocol. Eight of these patients were refractory to the LNH 84 induction regimen, 10 were partial responders and the six remaining attained complete response after LNH 84 induction but relapsed during consolidation therapy or after completing the whole programme. Twenty‐three patients were evaluable for response. The VIM regimen provided a 43 per cent complete response rate and an additional 17 per cent partial response rate. The complete response rate was particularly high (67 per cent) in the group of patients who were partial responders to LNH 84 induction treatment. Of the 10 complete responders, five relapsed after 4 to 42 months and five are still alive with no evidence of disease after 27 to 60 months. Overall VIM was well tolerated. Myelotoxicity was the most common side‐effect. Infections with fever were observed in 8 per cent of the VIM courses. This study demonstrates that a complete response and a long survival can be obtained in patients after failure of a high‐dose doxorubicin containing front‐line treatment.
VIM3‐ARA C: An effective salvage regimen in refractory or recurrent aggressive non hodgkin's lymphoma. A report on 18 cases
Authors: Dupriez Brigitte , Morel Pierre , Fenaux Pierre , Colcher‐Plantier Isabelle , Facon Thierry , Bauters Francis 
Published: February 2007

AbstractBased on encouraging results of previous combination regimens, we used a combination of VM26, ifosfamide, methylGAG, mitoxantrone (or adriamycin), high‐dose (HD) methotrexate and HD Ara C to treat 18 patients with relapsed or refractory NHL. Front‐line therapy had been in most of them a reinforced CHOP regimen. Twelve patients (67 per cent) responded: there were nine (50 per cent) partial responses (PR) and three (17 per cent) complete remissions (CR). Nine of these 12 responders were grafted (eight autologous. one allogeneic transplants), one relapsed before autograft could be performed and the two remaining patients were excluded from autograft because of positive bone marrow. Five of nine patients remained free of disease after 11 + to 27 + months. Response rate was higher in patients who relapsed ‘off’ therapy (2/3), but CR was also obtained in two refractory NHL and persisted for 11 + and 26+ months, suggesting that VIM3‐ARA C was, at least partially, non‐cross‐resistant with front‐line adriamycin‐containing regimens.
Pediatric non‐hodgkin's lymphoma abdominal presentations: A comparative study between two treatment regimens at the national cancer institute cairo
Authors: Hadi Salah S. Abdel , Taneer Omar M. El , Hussein Mohamed H. , Haddad Alaa El , Badawi Sami El , Mokhtar Nadia , Hamza M. R. , Gad Mawla N. El 
Published: February 2007

AbstractAbdominal presentations of pediatric NHL are rarely amenable to complete surgical resection. Chemotherapy is the hallmark of treatment for pediatric NHL. Treatment of various types of this disease including intra‐abdominal NHL in children with various protocols have not exceeded 54 per cent two‐year disease‐free survival.We have attempted to study and compare the effects of two treatment regimen upon two groups of previously untreated children up to the age of 16 years who presented to the Pediatric Oncology Unit at the NCI. The first group included 18 children who presented between 1983 and 1985 and were treated by a modified St Jude regimen: while the second group of patients was comprised of 19 children who presented between 1985 and 1987 and were treated by a multi‐national protocol: the MCP 842.The two groups will be compared with respect to various patient characteristics, response to therapy and their two‐year disease‐free survival as well as overall survival.
Gastric cancer—surgical approach
Authors: Weese James L. , Nussbaum Michael L. 
Published: February 2007

AbstractAlthough the incidence of carcinoma of the stomach has steadily declined over the last 50 years. approximately 23 200 new cases will be diagnosed in the United States this year and 13 700 patients will die. Despite marked improvement in operative techniques, fewer than 20 per cent of those diagnosed with gastric cancer beyond the most superficial levels of invasion will survive for over five years. Gastric tumours spread by local, lymphatic, and aggressive intra‐peritoneal routes as well as hematogenous dissemination. Over 87 per cent of recurrences have local or regional components.Radiation therapy may decrease local and regional recurrences in those patients with transmural tumours. The neoadjuvant use of etoposide, adriamycin, and platinum may yield complete clinical and pathologic responses in patients found to have ‘unresectable’ tumours. Other chemotherapy regimens have been shown to have some effect on advanced disease and may have a role in the neoadjuvant setting.Our current recommendations for the treatment of gastric cancer in a controlled trial setting would be neoadjuvant chemotherapy followed by R2 resection, postoperative intraoperative radiation therapy with the possibility of postoperative ± chemotherapy. Hopefully, this aggressive multimodality approach will significantly improve the five year survival for this disease.
Specific cutaneous involvement in Hodgkin's disease
Authors: Tassies Dolors , Sierra Jorge , Montserrat Emilio , Marti Rosa , Estrach Teresa , Rozman Ciril 
Published: February 2007

AbstractIn Hodgkin's disease (HD) specific cutaneous involvement is rare. When it occurs, retrograde lymphatic spread, direct extension from the underlying lymph nodes, and hematogenous dissemination are the mechanisms usually implicated. Among 349 patients with HD diagnosed and followed‐up at our institution from 1969 to 1990, three (0·85 per cent) presented specific cutaneous involvement. In two cases with mixed cellularity subtype, skin lesions displayed histologic features similar to those found in the lymph node. Treatment with combination chemotherapy resulted in rapid disappearance of the lesions in two patients but was ineffective in the third. Previous reports of cutaneous involvement in HD, its differential diagnosis. prognostic significance, and treatment are briefly reviewed.
Failure of IMVP‐16 as second‐line treatment for relapsed or refractory high grade non‐hodgkin's lymphoma
Authors: De Lord C. , Newland A. C. , Linch D. C. , Hudson B. Vaughan , Hudson G. Vaughan 
Published: February 2007

AbstractThe British National Lymphoma Investigation (BNLI) has assessed the use of an IMVP‐16 regimen (ifosfamide, methotrexate, VP‐16) in 46 patients with high grade non‐Hodgkin's lymphoma (NHL) who on first‐line chemotherapy either failed to attain a complete remission or relapsed. Seventeen patients responded to IMVP‐16 but only five (11 per cent) went into a complete remission (CR), 12 (26 per cent) had a partial remission (PR) and 29 (63 per cent) showed no response (NR). CR after IMVP‐16 has been maintained in only one case (36 months). The results of this study imply that the use of this IMVP‐16 protocol as second‐line treatment for patients with recurrent high grade NHL is unsuccessful and alternative salvage regimens should be sought.
Etoposide in combination with intermediate dose cytosine arabinoside (ID ARA C) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy
Authors: Whelan J. S. , Davis C. L. , Rohatiner A. Z. S. , Leahy M. , Maccallum P. K. , Gupta R. K. , Matthews J. , Norton A. J. , Amess J. A. L. , Lister T. A. 
Published: February 2007

AbstractThirty‐four patients with refractory or recurrent high grade non‐Hodgkin's lymphoma (NHL) or acute leukemia were treated with a combination of etoposide, 100 mg/m2 daily, and ara C, 1 g/m2 twice daily, for 5 days (VPARAC). This therapy was given in the anticipation that remissions thus achieved would be ‘consolidated’ with myeloablative therapy supported by bone marrow transplantation (BMT). The complete remission rate (CR) in patients with NHL was 3/18 (17 per cent) with partial responses (PR) seen in a further four patients, giving an overall response rate of 39 per cent. Four patients (three in CR, one in PR) proceeded to the planned consolidation treatment. Complete remission was achieved in 2/8 (25 per cent) patients with acute myelogenous leukemia (AML) and in 2/8 patients with acute lymphoblastic leukemia (ALL). Three of these patients subsequently had myeloablative consolidation therapy with BMT. There were four treatment‐related deaths (NHL, two; AML, one; ALL, one). In poor risk patients with high grade NHL and acute leukemia, VPARAC is an effective remission induction programme in 21 per cent of patients. Seven of the original 34 patients received the intended ‘curative’ therapy, of whom only four are alive and well 1 year later.
A new monoclonal antibody which binds to the cytoplasm of large cell lymphomas
Authors: Nakamura Naoya , Suzuki Sayuri , Ono Nobutaka , Tominaga Kunihiko , Hojo Hiroshi , Abe Masafumi , Wakasa Haruki 
Published: February 2007

AbstractWe reported a new monoclonal antibody, designated FUB‐1, reacting with normal and neoplastic large lymphoid cells. FUB‐1 was produced using a Burkitt's lymphoma cell line (HBL‐5) as an immunogen. Its immunoglobulin subtype was IgM. The determinant was not on the surface but in the cytoplasm. Western blotting analysis revealed that the molecular weight of the antigen was 52000 dalton. In the normal lymphoid tissue, FUB‐1 reacted with large lymphoid cells, but not with small or medium‐sized lymphoid cells or plasma cells. In addition, the FUB‐1 antigen was not found in resting cells in the peripheral blood (PB), but it was induced on mononuclear cells of PB by addition of PWM or PMA. In the B‐cell lymphomas tested, FUB‐1 reacted with small cleaved cell lymphomas (3/12), large cell lymphomas (7/10), Burkitt's lymphomas (4/4) and immunoblastic lymphomas (2/2), but not with small cell lymphomas (0/3) or intermediate lymphocytic lymphomas (0/8). These findings indicate that the FUB‐1 antigen appears to be expressed on normal lymphoid cells during blastoid transformation and on neoplastic large lymphoid cells. FUB‐1 also reacted with normal glandular epithelium and various adenocarcinomas.FUB‐1 may be useful to investigate the mechanism of in vitro blastoid transformation or activation of lymphoid cells.
Intensive retreatment of adults and children with acute lymphoblastic leukemia
Authors: Bassan Renato , Cornelli Pier Emilio , Battista Raffaele , Terzi Fausto , Buelli Maurizio , Rambaldi Alessandro , Viero Piera , D'Emilio Anna , Dini Enrico , Barbui Tiziano 
Published: February 2007

AbstractTwenty‐three patients (16 adults) failing their first or subsequent (n= 8) intensive treatment for de novo acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia lymphoid blast phase (n = 2) were managed with protocol POG 8201, originally introduced in relapsed ALL of childhood. In this programme, a four‐drug induction phase is followed by early consolidation with teniposide‐cytarabine, intrathecal chemotherapy, continuation weekly chemotherapy alternating teniposide‐cytarabine with vincristine‐cyclophosphamide. and periodic reinduction courses. Fourteen adults and five children with ALL achieved a complete response (CR) (86 per cent). The highest response rate (100 per cent) was obtained in 12 patients treated at first relapse after an initial CR of greater than 18 months (p = 0.07). Median duration of CR was 8 months in adults and 11 months in children. A longer than previous one CR (inversion) was obtained in four cases. Four ALL patients were successfully transplanted from a matched sibling after 3–11 months from achievement of CR. Median overall survival in adults with ALL was 11 months, significantly longer than for 40 comparable cases treated intensively but without rotational continuation therapy in previous years (p< 0.001). This regimen is applicable to adults with relapsed ALL, where prolongation of survival may allow time for effective salvage with bone marrow transplantation.